Go to the list of all blogs
Scott Bell's Avatar
published in Blogs
Nov 19, 2026
TickeronGET DAILY SIGNALS
Why Is Aptevo Therapeutics (APVO) Stock Down -8.77% Today?

Why Is Aptevo Therapeutics (APVO) Stock Down -8.77% Today?

Key Takeaways

  • APVO shares fell 8.77% to $0.4069 in midday trading on November 19, reversing an early pre-market gain of more than 2%.
  • No fresh company announcement, filing or analyst action was identified for today's session; the dominant driver remains the dilution overhang from the November 11 warrant inducement financing.
  • That transaction raised just $3.0 million in gross proceeds but attached new warrants covering 13,888,890 shares — roughly five times the shares actually exercised — at $1.08 per share.
  • A secondary weight is the cash-burn picture: the company reported a third-quarter net loss of $6.55 million on November 16 with no product revenue.
  • Recent sessions have traded at multiples of the 20-day average volume of about 132,000 shares, and the stock is now at a new 52-week low after losing more than 98% of its value over twelve months.
  • News Significance Score: 20/100 — No new verified news today, and a decline only about twice the stock's typical daily swing.
  • Traders are watching the special stockholder meeting needed to make the new warrants exercisable, the December ASH data presentation for mipletamig, and whether the shares can reclaim $1.
  • For deeper detail on Price Targets, Earnings and forward-looking Forecast data, explore the dedicated pages on Tickeron.
  • Readers who want to see which algorithmic strategies are working right now can browse the curated Trending AI Robots list.

Opening Summary

Aptevo Therapeutics Inc. (APVO) is a Seattle-based clinical-stage biotechnology company developing bispecific and trispecific immuno-oncology therapies. Its lead candidate, mipletamig, is being tested in the RAINIER Phase 1b/2 trial in frontline acute myeloid leukemia in combination with venetoclax and azacitidine. The company has no product revenue and a market capitalization of roughly $1.1 million.

Shares last changed hands at $0.4069, down 8.77% from the prior session's close of $0.446 — a decline of about 3.9 cents. The direction is unambiguously negative. No company-specific news release was published during the session, so the move reflects the ongoing repricing of a heavily diluted equity rather than a discrete new event.

Dilution Overhang From the Warrant Inducement

The decisive development for the stock remains the November 11 warrant inducement agreement, which closed on November 12. Existing warrant holders agreed to exercise 2,777,778 warrants in cash at a repriced $1.08 per share, delivering approximately $3.0 million in gross proceeds. In return, Aptevo issued new unregistered warrants covering 13,888,890 shares — 500% of the exercised amount — at the same $1.08 strike, exercisable only after stockholder approval and expiring five years later.

For a company of this size, that structure is heavily dilutive relative to the cash raised. The potential $15.0 million of additional proceeds if every new warrant is exercised matters far less today than the near-fivefold increase in potential share count it represents. Crucially, the deal was struck at $1.08 while the stock now trades near $0.41, meaning every new warrant sits far out of the money and the overhang is likely to cap rallies rather than support them. The company has run a similar playbook before, including a comparable financing in August 2026 struck at $4.03, which itself followed a $60 million standby equity facility signed earlier in the year.

Cash Burn and the Financing Cycle

The November 16 third-quarter report added context rather than relief. Aptevo disclosed a net loss of $6.55 million for the quarter ended September 30, 2026, against no revenue, with a nine-month loss of $19.6 million. Against that burn rate, $3.0 million in gross proceeds represents weeks of runway, not a funded path to commercialization. Each successive capital raise has been priced lower than the last, and each has added share count, which explains why the equity has repriced so violently even as the underlying clinical narrative — an 81% remission rate in evaluable frontline AML patients — has not deteriorated.

Thin Liquidity and a Broken Technical Picture

With a float of only about 2.3 million shares, Aptevo's order book is thin enough that modest selling pressure produces outsized percentage moves. The stock has closed lower in seven of the last eight sessions and sits far below both its 50-day moving average near $1.51 and its 200-day moving average near $3.88. A relative strength index reading close to 10 places it in deeply oversold territory, yet buyers have repeatedly failed to hold intraday rebounds — the pattern seen again today, when an early pre-market advance above $0.45 gave way to a new 52-week low.

Market Context and Trading Activity

Volume in recent sessions has run well above the 20-day average of roughly 132,000 shares, with more than 395,000 shares changing hands on November 18 and roughly 281,000 on November 11, the day the financing was announced. That volume profile is consistent with distribution into strength rather than accumulation. The move was idiosyncratic: broad small-cap biotech indices and clinical-stage peers were not down by a comparable margin, and the decline cannot be attributed to sector or macro pressure. There were no meaningful support levels left beneath the price after the break below $0.50 earlier this week.

News Significance Score

The score runs from 0, meaning no meaningful news and a move that is normal for the stock, to 100, meaning transformative news and an extreme, rare price move. Aptevo lands at 20 out of 100.

The verified news backdrop is a small but genuinely dilutive financing for a company with a sub-$2 million valuation, already several sessions old and therefore largely reflected in the price. Today's decline of 8.77% was roughly twice the stock's average absolute daily move of about 4.5% over the past 60 sessions, and moves of that size or larger occurred seven times in that window. With no fresh catalyst and a repetition rate this high, both components score low and combine into a modest total.

What Comes Next for APVO

The nearest scheduled item is the special meeting of stockholders required to approve the inducement warrants; a preliminary proxy was filed on November 13. Approval would make the new warrants exercisable and formalize the overhang. Beyond that, investors will focus on the December 12–15 ASH annual meeting, where mipletamig data in frontline AML is expected to be presented, and on completion of the RAINIER trial by year-end, ahead of a planned Phase 2 start in 2027. Sustained trading below $1 also leaves the shares exposed to Nasdaq's minimum bid price requirement, a compliance risk that typically forces a reverse split. With one analyst covering the name and no revenue, headline risk in both directions remains elevated.

Trending AI Robots

Tickeron's Trending AI Robots page curates the strongest-performing algorithmic traders under current market conditions. The platform hosts hundreds of AI trading bots spanning thousands of tickers, and each bot differs by strategy, timeframe, performance metrics and the specific symbols it trades. Rather than listing the full catalog, this section highlights only the bots posting the best results right now, making it a practical starting point for investors who want to see how automated strategies are positioned. Review the current leaders and compare their track records before deciding what fits your approach.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: APVO

Contributor

Scott Bell's AvatarScott Bell|Expert

I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking


APVO's RSI Oscillator remains in oversold zone for 9 days

The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a +2.24% 3-day Advance, the price is estimated to grow further. Considering data from situations where APVO advanced for three days, in 141 of 186 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.

APVO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for APVO turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 43 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where APVO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for APVO entered a downward trend on November 18, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 52 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.366) is normal, around the industry mean (3.592). P/E Ratio (0.003) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (442.120).

The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 98 (best 1 - 100 worst), indicating slightly worse than average price growth. APVO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. APVO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -4%. For the same Industry, the average monthly price growth was -11%, and the average quarterly price growth was -24%. SLS experienced the highest price growth at 113%, while CUE experienced the biggest fall at -74%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 19%. For the same stocks of the Industry, the average monthly volume growth was -10% and the average quarterly volume growth was -21%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 67
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -4 (-100 ... +100)
1-on-1 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a provider of immunology and cancer research services

Industry Biotechnology

Industry
Biotechnology
Address
2401 4th Avenue
Phone
+1 206 838-0500
Employees
36
Web
https://www.aptevotherapeutics.com
Interact to see
Advertisement
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
AMD jumped +2.42%, rising $12.81 to $542.95 from Wednesday's close of $530.14, in early regular-session trading Thursday after extending gains built during premarket. The catalyst was Anthropic's IPO, priced at $83 a share above its marketed range and raising $81.3 billion in the largest listing on record; the debut revived sentiment across AI hardware names, and AMD is both an Anthropic supplier and a $2.5 billion investor in the lab.
Cerebras Systems (CBRS) dropped -6.48% to $97.43 in regular trading from the prior close of $104.18, reversing an early premarket gain of roughly +3%. No verified news or fundamental catalyst found for the intraday reversal; the move is likely profit-taking after the stock's +21% post-earnings rebound, consistent with a name that averages a ±4.5% daily swing and remains 65% below its first-day close.
CBRS fell -6.07% to $97.86 in the opening minutes of Wednesday's regular session, down from Tuesday's close of $104.18 — the move occurred during market hours, not premarket or after-hours. No verified news or fundamental catalyst found: no new filing, contract, or analyst action explains the drop, which is likely continued give-back from the post-earnings pop and the stock's habitual volatility — CBRS has averaged a ±4.5% daily swing over the past 60 sessions, and 17 of those sessions moved as much or more.
KLAR dropped -4.84% to $13.75 from Wednesday's close of $14.45, with the decline occurring during Thursday's regular session. JPMorgan downgraded the shares to Hold from Overweight and cut its price target to $17 from $20 in a note published before the open, extending a run of post-earnings target reductions.